eLetters

322 e-Letters

  • A Case-control or a retrospective cohort study? Comment on the article by Martinez-Zamorra et al.
    Markus Bredemeier

    Dear Editor,

    I read with interest the study by Martinez-Zammora et al. (1), which reported an increased incidence of thrombotic events in patients with antiphospholipid syndrome with recurrent spontaneous abortion (APS-RSA group) in comparison with 3 different control groups. Although their conclusions seem to be valid, some comments may be appropriate.

    This study is labeled as 'case-control', but it is actual...

    Show More
  • Does Rheumatoid Synovitis Activity Vary During The Day? A sonographic and Doppler evaluation.
    Agnes Lhoste-Trouilloud

    Does Rheumatoid Synovitis Activity Vary During The Day? A sonographic and Doppler evaluation. A. Lhoste-Trouilloud1, B. Pereira2, M. Couderc3, S Mathieu3 , M. Soubrier3

    1 Radiology; 2DRCI; 3 Rheumatology Department, CHU Gabriel Montpied, Clermont-Ferrand, France

    Dear Editor,

    We read with interest the report of Semerano et al who describe a diurnal variation of power Doppler ultrasonography in the met...

    Show More
  • Association of malignancies with tumour necrosis factor inhibitors: real facts
    Srijit Das

    Dear Editor,

    We read with much interest the published article entitled 'Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis' by Mariette et al [1]. Beyond any doubt, autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus and psoriatic arthritis are associated with higher incidence of maligna...

    Show More
  • Comment on: Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy
    Shigeki Momohara

    Dear Editor,

    We read with interest the recent article by Galloway et al. investigating septic arthritis (SA) in rheumatoid arthritis (RA) patients enrolled in the British Society for Rheumatology Biologics Register (BSRBR), who received anti tumour necrosis factor (anti-TNF) therapy.[1]
    The results of their evaluation of data from the BSRBR indicated that anti -TNF therapy for RA is associated with a doubling of t...

    Show More
  • Septic arthritis in patients with rheumatoid arthritis and the effects of anti-TNF therapy.
    David M Grennan

    Dear Editor,

    We are interested in the risk of sepsis in prosthetic joints after the use of biologic purposes for RA. We were therefore interested to read the study by 'Galloway et al (1). Galloway and colleagues have used data from the BSR biologics registry to examine the frequency of septic arthritis in anti - TNF treated patients and have found that both anti TNF therapy and previous prosthetic joints increase the...

    Show More
  • Re:Neutrophils present in synovial fluids and tissues of rheumatoid arthritis are a major source of RANKL
    Dagmar Scheel-Toellner

    Dear Editor,

    We thank Poubelle et al for their interest in our publication "Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis "[1]
    We share an enthusiasm with Professor Poubelle for the role of neutrophils in the pathophysiology of rheumatoid arthritis and agree that neutrophils are often the dominant cell population in rheumatoid synovial fluid.

    However, we disagr...

    Show More
  • Is sifalimumab a human anti-IFN alpha monoclonal antibody with a potential therapy for systemic lupus erythematosus?
    Wang-Dong Xu

    Dear editor,

    Merrill, et al. [1] reported that sifalimumab with safety profile and clinical activity was used in the phase I, multicentre, double-blind randomised study as an anti-IFN alpha monoclonal antibody in systemic lupus erythematosus (SLE), in which sifalimumab neutralized overexpression of the type I IFN signature in SLE patients in a dose-dependent manner as well as USP18/ESI-1 were inhibited, providing furthe...

    Show More
  • Corrected version of the e-letter "Selection bias may have blunted the effect of atorvastatin on the progression of atherosclerosis in systemic lupus erythematosus patients: Commentary on the Lupus Prevention Atherosclerosis Study (LAPS) "
    Markus Bredemeier

    Dear editor,

    We read with interest the study by Petri et al. (1), which showed absence of effect of atorvastatin on the change in coronary artery calcium and carotideal intima media thickness in lupus patients treated for 2 years. Lupus was been considered a coronary heart disease (CHD) equivalent by some authors given the major increase of cardiovascular risk in this disease (2).

    The authors reported that patie...

    Show More
  • Comment on: Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy
    Kosei Kawakami

    Dear Editor,

    We read with interest the recent article by Davies et al. [1] reporting on venous thrombotic events (VTEs) in patients with rheumatoid arthritis (RA) treated with antitumour necrosis factor (anti-TNF). They suggest that anti-TNF therapy is not associated with an increased risk of VTEs in RA patients, although, until the present time, retrospective studies looking at VTEs in anti-TNF-treated RA patients have...

    Show More
  • Neutrophils present in synovial fluids and tissues of rheumatoid arthritis are a major source of RANKL
    Patrice E. Poubelle

    Dear Editor,

    In a paper recently published online (Ann Rheum Dis, doi: 10.1136/ard.2011.153312), the authors found that B lymphocytes from rheumatoid arthritis (RA) synovial fluids and tissues expressed RANKL.
    They stated that B cells were a major source of this cytokine in RA without considering that certain other synovial fluid cells and tissular cells have been reported to express RANKL in RA. In fact, they did...

    Show More

Pages